Loading…
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $124M | $-46M | $-39M | $-27M | -16.6% | 63.5% | -46.9% |
| 2024 | $76M | $-73M | $-73M | $38M | -32.6% | - | -46.3% |
| 2023 | $0M | $-137M | $-135M | $-63M | -75.5% | - | 24.7% |
| 2022 | $0M | $-109M | $-109M | $-105M | -40.0% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 75.62 | 123.67 |
| Operating Revenue | - | 0 | 0 | 75.62 | 123.67 |
| Operating Expense | - | 112.38 | 143.31 | 156.73 | 177.88 |
| Research And Development | - | 85.06 | 111.27 | 121.56 | 141.50 |
| Selling General And Administration | - | 27.32 | 32.04 | 35.17 | 36.38 |
| Total Expenses | - | 112.38 | 143.31 | 156.73 | 177.88 |
| Operating Income | - | -112.38 | -143.31 | -81.11 | -54.21 |
| Total Operating Income As Reported | - | -112.38 | -143.31 | -81.11 | -54.21 |
| EBITDA | - | -108.64 | -137.09 | -72.99 | -45.85 |
| Normalized EBITDA | - | -108.76 | -136.05 | -73.41 | -47.40 |
| EBIT | - | -112.38 | -143.31 | -81.11 | -54.21 |
| Interest Income | - | 3.76 | 9.33 | 10.57 | 12.94 |
| Net Interest Income | - | 3.76 | 9.33 | 10.57 | 12.94 |
| Other Non Operating Income Expenses | -0.96 | - | - | - | - |
| Other Income Expense | - | 0.12 | -1.04 | 0.42 | 1.54 |
| Interest Income Non Operating | - | 3.76 | 9.33 | 10.57 | 12.94 |
| Net Non Operating Interest Income Expense | - | 3.76 | 9.33 | 10.57 | 12.94 |
| Pretax Income | - | -108.50 | -135.01 | -70.13 | -39.72 |
| Tax Provision | - | 0 | 0.34 | 2.57 | -1.10 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -0.22 | 0.09 | 0.04 |
| Net Income Continuous Operations | - | -108.50 | -135.35 | -72.70 | -38.63 |
| Net Income From Continuing And Discontinued Operation | - | -108.50 | -135.35 | -72.70 | -38.63 |
| Net Income From Continuing Operation Net Minority Interest | - | -108.50 | -135.35 | -72.70 | -38.63 |
| Net Income | - | -108.50 | -135.35 | -72.70 | -38.63 |
| Net Income Common Stockholders | - | -108.50 | -135.35 | -72.70 | -38.63 |
| Net Income Including Noncontrolling Interests | - | -108.50 | -135.35 | -72.70 | -38.63 |
| Normalized Income | - | -108.62 | -134.53 | -73.03 | -40.13 |
| Diluted NI Availto Com Stockholders | - | -108.50 | -135.35 | -72.70 | -38.63 |
| Basic Average Shares | 25 | 47.23 | 51.40 | 61.51 | - |
| Diluted Average Shares | 25 | 47.23 | 51.40 | 61.51 | - |
| Reconciled Depreciation | - | 3.74 | 6.22 | 8.12 | 8.36 |
| Total Unusual Items | - | 0.12 | -1.04 | 0.42 | 1.54 |
| Total Unusual Items Excluding Goodwill | - | 0.12 | -1.04 | 0.42 | 1.54 |
| Special Income Charges | - | 0.11 | 0.02 | 0 | 0.06 |
| Gain On Sale Of Security | - | 0.01 | -1.06 | 0.42 | 1.48 |
| General And Administrative Expense | - | 27.32 | 32.04 | 35.17 | 36.38 |
| Other Gand A | - | 11.94 | 12.39 | 13.02 | 13.40 |
| Salaries And Wages | - | 15.39 | 19.65 | 22.15 | 22.98 |
| Gain On Sale Of Ppe | - | 0.11 | 0.02 | 0 | 0.06 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc.this co. | GLUE | $1.5B | -37.97 | 6.29 | -16.6% | -30.01 |
| AnaptysBio, Inc. | ANAB | $1.5B | - | 40.41 | -35.6% | 17.42 |
| STAAR Surgical Company | STAA | $1.5B | -18.48 | 4.32 | -23.4% | -36.86 |
| Perrigo Company plc | PRGO | $1.5B | -1.04 | 0.50 | -48.6% | -5.75 |
| NeoGenomics, Inc. | NEO | $1.5B |
| - |
| - |
| - |
| - |
| - |
| -13.63 |
| 1.76 |
| -12.9% |
| -44.52 |
| MBX Biosciences, Inc. | MBX | $1.5B | -16.92 | 3.98 | -23.6% | -14.28 |
| Aveanna Healthcare Holdings Inc. | AVAH | $1.4B | 6.42 | 7.40 | 115.3% | 10.26 |
| Septerna, Inc. | SEPN | $1.4B | -28.93 | 3.70 | -12.8% | -16.63 |
| Maze Therapeutics, Inc. | MAZE | $1.4B | -10.72 | 3.96 | -36.9% | -8.82 |
| Peer Median | - | -13.63 | 3.97 | -23.5% | -11.55 | |